Integrating the tools for an individualized prognosis in multiple sclerosis

Journal of the Neurological Sciences

Volumn 331, Issue 1-2, 2013, Pages 10-13

  Fernandez O ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Bioinformatics; Biomarker; Individualized medicine; Multiple sclerosis; Personalized medicine; Prognosis

Indexed keywords

CHITINASE; CHITINASE 3 LIKE 1; IMMUNOGLOBULIN M; MYELIN; UNCLASSIFIED DRUG;

BRAIN ATROPHY; BRAIN DAMAGE; DISABILITY; DISEASE COURSE; DISEASE EXACERBATION; GRAY MATTER; MULTIPLE SCLEROSIS; NEUROFILAMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REVIEW; RISK FACTOR; WHITE MATTER;

EID: 84882449149     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2013.04.021     Document Type: Review

References (40)

1. Villoslada P. Biomarkers formultiple sclerosis. Drug News Perspect Nov 2010;23(9): 585-95.
2. Graber JJ, Dhib-Jalbut S. Biomarkers of disease activity in multiple sclerosis. J Neurol Sci Jun 15 2011;305(1-2):1-10.
3. Rothberg JM, Hinz W, Rearick TM, Schultz J, Mileski W, Davey M, et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature 2011;474:348-52.
4. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol May 2005;4(5):281-8.
5. Lublin FD. The incomplete nature of multiple sclerosis relapse resolution. J Neurol Sci May 15 2007;256(Suppl. 1):S14-8.
6. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain Dec 1989;112(Pt 6):1419-28.
7. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain Apr 2003;126(Pt 4):770-82.
8. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med Nov 16 2000;343(20):1430-8.
9. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology Apr 12 2005;64(7):1144-51.
10. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med Nov 16 2000;343(20):1430-8.
11. Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology Jan 24 2006;66(2):172-7.
12. Sayao AL, Devonshire V, Tremlett H. Longitudinal follow-up of "benign" multiple sclerosis at 20 years. Neurology Feb 13 2007;68(7):496-500.
13. West T, Wyatt M, High A, Bostrom A, Waubant E. Are initial demyelinating event recovery and time to second event under differential control? Neurology Sep 12 2006;67(5):809-13.
14. Villar LM, Masjuan J, González-Porqué P, Plaza J, Sádaba MC, Roldán E, Bootello A, Alvarez-Cermeño JC. Intrathecal IgM synthesis in neurologic diseases: relationship with disability in MS. Neurology Mar 12 2002;58(5):824-6.
15. Villar LM, Masjuan J, González-Porqué P, Plaza J, Sádaba MC, Roldán E, Bootello A, Alvarez-Cermeño JC. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology Aug 27 2002;59(4):555-9.
16. Villar L, García-Barragán N, Espiño M, Roldán E, Sádaba M, Gómez-Rial J, González-Porqué P, Alvarez-Cermeño J. Influence of oligoclonal IgM specificity in multiple sclerosis disease course.Mult Scler Mar 2008;14(2):183-7 [Villar et al. Mult Scler 08].
17. Perini P, Ranzato F, Calabrese M, Battistin L, Gallo P. Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis. J Neurol Neurosurg Psychiatry Aug 2006;77(8):953-5.
18. Jongen PJ, Lycklama A, Nijeholt G, Lamers KJ, Doesburg WH, Barkhof F, Lemmens WA, Klasen IS, Hommes OR. Cerebrospinal fluid IgM index correlates with cranial MRI lesion load in patients with multiple sclerosis. Eur Neurol 2007;58(2):90-5.
19. Mandrioli J, Sola P, Bedin R, Gambini M, Merelli E. A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease. J Neurol Jul 2008;255(7):1023-31.
20. Durante L, Zaaraoui W, Rico A, Crespy L, Wybrecht D, Faivre A, Reuter F, Malikova I, Pommier G, Confort-Gouny S, Cozzone PJ, Ranjeva JP, Pelletier J, Boucraut J, Audoin B. Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual. Mult Scler May 2012;18(5):587-91.
21. Thangarajh M, Gomez-Rial J, Hedström AK, Hillert J, Alvarez-Cermeño JC, Masterman T, Villar LM. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. Mult Scler Nov 2008;14(9):1208-13.
22. Gresle MM, Butzkueven H, Shaw G. Neurofilament proteins as body fluid biomarkers of neurodegeneration in multiple sclerosis. Mult Scler Int 2011;2011:315406.
23. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med Jul 10 2003;349(2):139-45.
24. Cantó E, Reverter F, Morcillo-Suárez C, Matesanz F, Fernández O, Izquierdo G, Vandenbroeck K, Rodríguez- Antigüedad A, Urcelay E, Arroyo R, Otaegui D, Olascoaga J, Saiz A, Navarro A, Sánchez A, Domínguez C, Caminero A, Horga A, Tintoré M, Montalban X, Comabella M. Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis. Mult Scler Dec 19 2011 [Epub ahead of print].
25. Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, Thompson AJ, Miller DH. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain Mar 2008;131(Pt 3):808-17.
26. Minneboo A, Barkhof F, Polman CH, Uitdehaag BM, Knol DL, Castelijns JA. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol Feb 2004;61(2):217-21.
27. Tintoré M, Rovira A, Río J, Nos C, Grivé E, Téllez N, Pelayo R, Comabella M, Sastre-Garriga J, Montalban X. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology Sep 26 2006;67(6):968-72.
28. Tam RC, Traboulsee A, Riddehough A, Sheikhzadeh F, Li DK. The impact of intensity variations in T1-hypointense lesions on clinical correlations in multiple sclerosis. Mult Scler Aug 2011;17(8):949-57.
29. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology Nov 10 1999;53(8):1698-704.
30. De Stefano N, Giorgio A, Battaglini M, Rovaris M, Sormani MP, Barkhof F, Korteweg T, Enzinger C, Fazekas F, Calabrese M, Dinacci D, Tedeschi G, Gass A, Montalban X, Rovira A, Thompson A, Comi G, Miller DH, Filippi M. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology Jun 8 2010;74(23):1868-76.
31. Rudick RA, Lee JC, Nakamura K, Fisher E. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci Jul 15 2009;282(1-2):106-11.
32. van den Elskamp IJ, Knol DL, Vrenken H, Karas G, Meijerman A, Filippi M, Kappos L, Fazekas F, Wagner K, Pohl C, Sandbrink R, Polman CH, Uitdehaag BM, Barkhof F. Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis. Mult Scler Jun 2010;16(6):660-9.
33. De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP, Matthews PM, Arnold DL. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol Jan 2001;58(1):65-70.
34. Calabrese M, De Stefano N, Atzori M, Bernardi V, Mattisi I, Barachino L, Morra A, Rinaldi L, Romualdi C, Perini P, Battistin L, Gallo P. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol Oct 2007;64(10):1416-22.
35. Saidha S, Syc SB, Ibrahim MA, Eckstein C, Warner CV, Farrell SK, Oakley JD, Durbin MK, Meyer SA, Balcer LJ, Frohman EM, Rosenzweig JM, Newsome SD, Ratchford JN, Nguyen QD, Calabresi PA. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain Feb 2011;134(Pt 2):518-33.
36. Vucic S, Burke T, Lenton K, Ramanathan S, Gomes L, Yannikas C, Kiernan MC. Cortical dysfunction underlies disability in multiple sclerosis. Mult Scler Apr 2012;18(4): 425-32.
37. Mandrioli J, Sola P, Bedin R, Gambini M, Merelli E. A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease. J Neurol Jul 2008;255(7):1023-31.
38. Sormani MP, Rovaris M, Comi G, Filippi M. A composite score to predict shortterm disease activity in patients with relapsing-remitting MS. Neurology Sep 18 2007;69(12):1230-5.
39. Bejarano B, Bianco M, Gonzalez-Moron D, Sepulcre J, Goñi J, Arcocha J, Soto O, Del Carro U, Comi G, Leocani L, Villoslada P. Computational classifiers for predicting the short-term course of multiple sclerosis. BMC Neurol Jun 7 2011;11:67.
40. Daumer M, Neuhaus A, Herbert J, Ebers G. Prognosis of the individual course of disease: the elements of time, heterogeneity and precision. J Neurol Sci Dec 2009;287(Suppl. 1):S50-5.